RecruitingPhase 4NCT06261840

Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole

Refining Treatment Options for Trichomonas Vaginalis Infection in Women and Men: A Comparative Analysis of Oral Multi-Dose Metronidazole and Single-Dose Secnidazole

Sponsor

Tulane University

Enrollment

1,200 participants

Start Date

May 6, 2025

Study Type

INTERVENTIONAL

Conditions

Trichomonas Vaginitis Bacterial Vaginitis

Summary

This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the treatment of Trichomonas vaginalis in both women and men.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Metronidazole 500 mg and a drug called Secnidazole 2000 MG for people with bacterial vaginitis and trichomonas vaginitis. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMetronidazole 500 mg

Multi-dose oral MTZ (500 mg twice daily for 7 days) for the treatment of T. vaginalis infection in women and men

DRUGSecnidazole 2000 MG

Single-dose 2 g oral SEC for the treatment of T. vaginalis infection in women and men

Locations(4)

University of Alabama at Birmingham [UAB] Gynecology Clinics

Birmingham, Alabama, United States

UAB Sexual Health Research Clinic [SHRC]

Birmingham, Alabama, United States

Segal Trials Healthcare Clinical Data, Inc. 1065 NE 125th St. Suite 417 North Miami, FL 33161

North Miami, Florida, United States

LSU-CrescentCare Sexual Health Center

New Orleans, Louisiana, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06261840